Cypre’s CEO, Kolin Hribar, was interviewed by the CRL Eureka blog on the future of oncology drug development, and how 3D models will play a central role in determining the next set of cancer immunotherapies.
Cypre’s CEO, Kolin Hribar, was interviewed by the CRL Eureka blog on the future of oncology drug development, and how 3D models will play a central role in determining the next set of cancer immunotherapies.